Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE PLAIN versus X TROZINE L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE PLAIN versus X TROZINE L A.
PROMETHAZINE PLAIN vs X-TROZINE L.A.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts primarily as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and local anesthetic properties. Its antiemetic effect is mediated through blockade of dopamine D2 receptors in the chemoreceptor trigger zone.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
25-50 mg orally, intramuscularly, or rectally every 4-6 hours as needed; maximum 100 mg per dose
250 mg orally once daily. May be increased to 500 mg once daily if needed.
None Documented
None Documented
Terminal elimination half-life: 10-19 hours (average 12-15 hours). Clinical context: Requires repeated dosing for sustained effect; dosing interval typically every 6-12 hours.
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for approximately 25-30%.
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine